Teachers Retirement System of The State of Kentucky purchased a new stake in Hologic, Inc. (NASDAQ:HOLX – Get Rating) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 111,874 shares of the medical equipment provider’s stock, valued at approximately $7,219,000.
A number of other large investors also recently modified their holdings of the company. Salem Investment Counselors Inc. raised its position in Hologic by 163.9% during the 2nd quarter. Salem Investment Counselors Inc. now owns 549 shares of the medical equipment provider’s stock worth $38,000 after purchasing an additional 341 shares during the last quarter. Lansing Street Advisors bought a new position in shares of Hologic in the 3rd quarter worth about $44,000. Neo Ivy Capital Management bought a new position in shares of Hologic in the 2nd quarter worth about $56,000. Quadrant Capital Group LLC raised its position in shares of Hologic by 23.2% in the 2nd quarter. Quadrant Capital Group LLC now owns 929 shares of the medical equipment provider’s stock worth $64,000 after acquiring an additional 175 shares in the last quarter. Finally, Private Trust Co. NA bought a new position in shares of Hologic in the 2nd quarter worth about $64,000. 95.17% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
HOLX has been the subject of several research analyst reports. JPMorgan Chase & Co. lifted their price objective on Hologic from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Thursday, February 2nd. SVB Leerink lifted their price objective on Hologic from $90.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 2nd. Citigroup raised their target price on Hologic from $75.00 to $85.00 and gave the company a “neutral” rating in a research note on Thursday, February 2nd. Mizuho raised their target price on Hologic from $77.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, January 24th. Finally, Morgan Stanley raised their target price on Hologic from $74.00 to $81.00 and gave the company an “equal weight” rating in a research note on Friday, February 3rd. Eight investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Hologic currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.08.
Hologic Trading Down 1.6 %
Hologic (NASDAQ:HOLX – Get Rating) last issued its earnings results on Wednesday, February 1st. The medical equipment provider reported $1.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.17. Hologic had a net margin of 22.17% and a return on equity of 25.12%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter in the previous year, the firm posted $2.17 EPS. The business’s revenue for the quarter was down 27.0% compared to the same quarter last year. Sell-side analysts expect that Hologic, Inc. will post 3.74 earnings per share for the current year.
Insider Buying and Selling at Hologic
In other Hologic news, insider Benjamin Jordan Cohn sold 9,128 shares of the business’s stock in a transaction on Tuesday, February 7th. The shares were sold at an average price of $85.28, for a total transaction of $778,435.84. Following the sale, the insider now owns 14,298 shares of the company’s stock, valued at approximately $1,219,333.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.66% of the company’s stock.
Hologic Company Profile
Hologic, Inc engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery.
- Get a free copy of the StockNews.com research report on Hologic (HOLX)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX – Get Rating).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.